A61P 3 - Drugs for disorders of the metabolism

Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2009
12/23/2009	CN100571525C Bamboo charcoal bag health-care tea
12/23/2009	CN100571519C Method for producing nutrition reinforced noodle by using spray sandwich technique
12/23/2009	CA2852177A1 Glucagon/glp-1 receptor co-agonists
12/23/2009	CA2728284A1 Glucagon/glp-1 receptor co-agonists
12/23/2009	CA2728202A1 Composition for addition to drinking water
12/23/2009	CA2728018A1 Quinoxalinedione derivatives
12/23/2009	CA2727923A1 Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
12/23/2009	CA2727914A1 Spirodiamine-diaryl ketoxime derivative technical field
12/23/2009	CA2727465A1 Improved peptide mediators of cholesterol efflux
12/23/2009	CA2727147A1 Glycosylated glp-1 peptide
12/23/2009	CA2726164A1 Wnt protein signalling inhibitors
12/22/2009	US7635769 Oligoribonucleotide derivatives for specific inhibition of gene expression
12/22/2009	US7635751 For development of pharmaceutical preparations such as neutral nerve function regulator, circulatory function regulator, a cardiac function regulator, an immune function regulator, a digestive organ function regulator, metabolic function regulator
12/22/2009	US7635703 as tyrosine, serine/threonine, cyclin-dependent kinases, HER protein; 5-{2-[3-[4-trifluoromethyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazol-4-yl]-vinyl}-pyridine-3-carbaldehyde; antiproliferative, antiinflammatory agent, neurodegenerative diseases
12/22/2009	US7635684 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
12/22/2009	US7635681 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
12/22/2009	US7635674 insulin and carrieres, a second pharmaceutical composition containing O-(3-piperidino-2-hydroxy-1-propyl)nicotinic amidoxime ( BGP-15) and carriers; prediabetic state, metabolic X-syndrome, insulin sensitivity, glucose tolerance, dislipidemia or diabetes mellitus
12/22/2009	US7635556 Methods for drug discovery, disease treatment, and diagnosis using metabolomics
12/22/2009	CA2502269C Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/22/2009	CA2474460C Pyridine- and quinoline-derivatives
12/22/2009	CA2452558C A synergistic pharmaceutical combination for the prevention or treatment of diabetes
12/22/2009	CA2444719C Method of production of an isomaltulose-containing enteral nutrient
12/22/2009	CA2415214C Phosphotetrahydropyran compounds
12/22/2009	CA2413026C Cold water soluble .beta.-glucan product and process for preparing the same
12/22/2009	CA2405593C Macrolides
12/22/2009	CA2385860C Composition comprising casein protein and whey protein
12/22/2009	CA2373909C Multilayer drug form release in the colon
12/22/2009	CA2369587C Solubilized pharmaceutical composition for parenteral administration
12/22/2009	CA2348395C Compositions comprising a mixture of bioflavonols
12/22/2009	CA2323607C Immunological methods to modulate myostatin in vertebrate subjects
12/22/2009	CA2290744C Cyclic diamine compounds and medicine containing the same
12/17/2009	WO2009152190A1 Escalating dosing regimen for effecting weight loss and treating obesity
12/17/2009	WO2009151626A1 Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
12/17/2009	WO2009151383A1 Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
12/17/2009	WO2009151125A1 Diagnosis and treatment of hepatic disorder
12/17/2009	WO2009151094A1 HUMAN β3 ADRENERGIC RECEPTOR LIGAND, AND FOOD OR PHARMACEUTICAL PRODUCT CONTAINING THE SAME
12/17/2009	WO2009151057A1 Process for production of antioxidant active substance
12/17/2009	WO2009150614A1 Tetrazole compounds as orexin receptor antagonists
12/17/2009	WO2009150550A2 Genetic component of complications in type 2 diabetes
12/17/2009	WO2009150331A1 Novel azabicyclic derivatives, preparation method for same, and pharmaceutical compositions containing same
12/17/2009	WO2009150196A1 N-thiazolyl-1, 2, 3, 4-tetrahydro-6-isoquinolinecarboxamide derivatives as inhibitors of stearoyl coenzyme a desaturase
12/17/2009	WO2009150144A1 New gpr119modulators
12/17/2009	WO2009150109A1 Imidazolidine derivatives
12/17/2009	WO2009149820A1 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
12/17/2009	WO2009149819A1 Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
12/17/2009	WO2009149795A2 Heterocyclic cyclopropyl-substituted fxr binding compounds
12/17/2009	WO2009149585A1 Compositions for reducing blood glucose level and uses thereof
12/17/2009	WO2009149496A1 Treatment of diabetes and complications thereof and related disorders
12/17/2009	WO2009117669A3 Treatment with opioid antagonists and mtor inhibitors
12/17/2009	WO2009105548A3 Methods for treating and diagnosing diabetes
12/17/2009	WO2009051706A3 Peptide compounds for treating obesity and insulin resistance
12/17/2009	WO2009046834A3 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
12/17/2009	WO2009043481A3 Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009	WO2009043439A3 Use of retrocyclin- 1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009	WO2009043437A3 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections
12/17/2009	WO2009040072A3 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis
12/17/2009	WO2009040071A3 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis
12/17/2009	WO2009040029A3 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
12/17/2009	WO2009040028A3 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis
12/17/2009	WO2009039968A3 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection
12/17/2009	WO2009039966A3 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection
12/17/2009	WO2009039957A3 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection
12/17/2009	WO2009033796A8 Use of a peptide as a therapeutic agent
12/17/2009	WO2009033707A3 Use of retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
12/17/2009	WO2009033661A3 Use of rgdspasskp and optionally angiotensin ii as therapeutic agents in the treatment of eg s. pneumoniae infections
12/17/2009	WO2008109727A8 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
12/17/2009	US20090312543 Pyrazole compounds useful as protein kinase inhibitors
12/17/2009	US20090312419 CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE
12/17/2009	US20090312409 Lipopexia inhibitor and food or beverage
12/17/2009	US20090312397 RNAi Modulation Of ApoB And Uses Thereof
12/17/2009	US20090312390 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
12/17/2009	US20090312372 Chemical compounds
12/17/2009	US20090312350 Compositions comprising balaglitazone and further antidiabetic compounds
12/17/2009	US20090312345 Pharmacological chaperones for treating obesity
12/17/2009	US20090312334 Immunomodulating Heterocyclic Compounds
12/17/2009	US20090312319 Certain chemical entities, compositions and methods
12/17/2009	US20090312313 Compound having tgfbeta inhibitory activity and pharmaceutical composition comprising the same
12/17/2009	US20090312307 Heterocyclo inhibitors of potassium channel function
12/17/2009	US20090312303 Antidiabetic Bicyclic Compounds
12/17/2009	US20090312294 Method and Agent for Reducing Weight, Accelerating Lipid Catabolism, and/or Restricting Calories
12/17/2009	US20090312287 Multi-carotenoids compositions and methods
12/17/2009	US20090312286 Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
12/17/2009	US20090312255 Stimulation of trpv1+ sensory neurons to control beta-cell stress and islet inflammation in diabetes
12/17/2009	US20090312245 SRA binding protein
12/17/2009	US20090312236 Pegylated insulin lispro compounds
12/17/2009	US20090312235 Method for producing insulin in the form of an oral preparation
12/17/2009	US20090311792 Fibroblast growth factor (FGF23) and methods for use
12/17/2009	US20090311353 Equal-containing fermentation product of soybean embryonic axis, and method for production thereof
12/17/2009	US20090311351 Composition containing a cereal milling product
12/17/2009	US20090311326 Pulmonary Insulin Crystals
12/17/2009	US20090311256 12 Human Secreted Proteins
12/17/2009	US20090311235 Use of Polymeric Materials with Other Substances for Improved Performance
12/17/2009	US20090311190 Self-assembled, micropatterned, and radio frequency (rf) shielded biocontainers and their uses for remote spatially controlled chemical delivery
12/17/2009	CA2763548A1 Brown adipocyte progenitors in human skeletal muscle
12/17/2009	CA2727795A1 Genetic component of complications in type 2 diabetes
12/17/2009	CA2727373A1 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
12/17/2009	CA2727319A1 Low dose topiramate/phentermine composition and methods of use thereof
12/17/2009	CA2727313A1 Escalating dosing regimen for effecting weight loss and treating obesity
12/17/2009	CA2727223A1 Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
12/17/2009	CA2726102A1 Tetrazole compounds as orexin receptor antagonists

1 ... 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 ... 1298